RecruitingPhase 2NCT06081049
The COLchicine HEART Failure PRESERVED Trial (COLHEART-PRESERVED)
Sponsor
Tor Biering-Sørensen
Enrollment
152 participants
Start Date
Jan 18, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to investigate the effects of colchicine on heart failure related health status, quality of life, and vascular and cardiac function in patients with heart failure with preserved ejection fraction (HFpEF).
Eligibility
Min Age: 40 Years
Plain Language Summary
Simplified for easier understanding
This study tests whether colchicine — a common anti-inflammatory medication used for gout — can help people with heart failure with preserved ejection fraction (a type of heart failure where the heart pumps normally but is too stiff). Researchers believe reducing inflammation may ease symptoms.
**You may be eligible if...**
- You have been diagnosed with heart failure with a preserved pumping function (ejection fraction of 45% or more)
- You have had heart failure symptoms for at least 30 days and currently have symptoms (shortness of breath, fatigue)
- Your echocardiogram shows structural heart changes consistent with this type of heart failure
- Your BNP blood test level is elevated
- Your BMI is under 40
**You may NOT be eligible if...**
- You are already taking colchicine for gout or another reason
- You are allergic to colchicine
- You have very high blood pressure, severe liver disease, or kidney disease (low kidney function)
- You have a history of cancer (except some skin cancers)
- You have recently been hospitalized for heart failure, heart attack, or major cardiac surgery
- You are pregnant, breastfeeding, or planning pregnancy
- You have inflammatory bowel disease or chronic diarrhea
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGColchicine
0.5 mg once daily
DRUGPlacebo
Once daily
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06081049
Related Trials
Manganese-enhanced Magnetic Resonance Imaging (MEMRI) in Heart Failure With Preserved Ejection Fraction
NCT066527631 location
Fast Induced Remodeling in Heart Failure With Preserved Ejection Fraction
NCT058397308 locations
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
NCT07037459596 locations
A Study of 68Ga-Fibroblast Activation Protein Inhibitor (FAPI) Positron Emission Tomography in Heart Failure
NCT070830111 location
Novel Approaches for Improving Vascular Function in Veterans With HFpEF
NCT063127481 location